Chuangyebang was informed that recently, Jiangxi Shantai Health Industry Development Co., Ltd. announced the completion of tens of millions of yuan in Series A financing. This round of financing is exclusively invested by Shanghai Huihong Capital. The funds are mainly used for the clinical research of intestinal bacteria transplantation in tumors, autism, and infectious diseases, the development of microecological drug pipelines, the construction of teams and market channels, and the construction of immune microecological technology. It is the core industrial innovation service platform.
The founder and chairman of Shantai Health, Mr. Wang Jingsu, once served as the deputy director of the Management Committee of Taizhou National Pharmaceutical High-tech Zone. In 2016, Mr. Wang Jingsu resigned from office to pursue research and development, focusing on technology research and development, transformation and industrialization in the field of immune microecology. In January 2018, he came to Nanchang to establish Jiangxi Shanxing Biotechnology Co., Ltd. to carry out the research, promotion and application of intestinal flora transplantation project.
In the same year, the company’s industrialization project team was awarded the “Double Thousand Plan” high-level talent introduction team by the Jiangxi Provincial Government, and Mr. Wang Jingsu was awarded the “Hongcheng Plan” top-notch talent by the Nanchang Municipal Government. In March 2019, Ganzhou Shanjian Biotechnology Co., Ltd. was established in Ganzhou, Jiangxi Province, and began to screen and prepare intestinal flora donors in the mountainous area of southern Gansu, and created the first domestic mountain children’s intestinal flora donor bank.
Shantai Health is committed to technology research and development, clinical medicine and health management in the field of microecology, and empowers health tourism with the core technology of immune microecology. Build an immune micro-ecological industry chain complex, and work with the Jiangxi Shangrao International Medical Tourism Pilot Zone Management Committee to build the country’s first immune micro-ecological industry technology innovation port, and establish an industrial platform for new medical and health services.
Chairman Wang Jingsu said that after years of intensive cultivation, Suntech Health has mature core technologies in the screening, preparation, storage and transplantation of intestinal flora. After completing this round of financing, the company will continue to expand the healthy flora in the southern mountainous area of Gansu. The production capacity of the library focuses on the research and application of intestinal bacteria transplantation technology in the field of disease and the development of microecological drug pipelines. Taking the construction of “Immune Micro-ecological Innovation Port” as an opportunity, Suntech Health will be built into a new comprehensive health service industry base that integrates “research, medical treatment, industry, and health care”.
media coverage
Start -up in the investment world
Related events
- “Shantai Health” completed tens of millions of yuan in Series A financing, and Huihong Capital invested exclusively 2022-08-09
- Weimei Health has received tens of millions of RMB in angel round financing2022-05-11
- Hefei Tiangang completes hundreds of millions of yuan in Pre-A round financing2022-04-25
- Guoxin Health and Miao Health start strategic cooperation to jointly create a new plan for digital health management2021-08-11
- Huanyi Bio announced the completion of tens of millions of yuan in angel round financing2020-12-28
This article is reproduced from: https://readhub.cn/topic/8ikJhs5kvIt
This site is for inclusion only, and the copyright belongs to the original author.